

## PRISTINE BIOLOGICALS (NZ) LIMITED

(A wholly owned subsidiary of Indian Immunologicals Limited)

<b>Statement of Financial Performance</b>			
<b>For the year ended 31<sup>st</sup> March 2023</b>			
<b>S.No.</b>	<b>PARTICULARS</b>	<b>Year 2023 (Amt in NZD)</b>	<b>Year 2022 (Amt in NZD)</b>
1.	Total Sales	31,44,654	33,02,457
2.	Cost of sales	20,16,325	19,23,540
	<b>Gross Surplus</b>	<b>11,28,329</b>	<b>13,78,917</b>
4.	Add: Other Income	6,717	1,693
5.	Less: Expenses	7,46,719	7,17,580
	<b>Net surplus/(deficit) before depreciation</b>	<b>3,87,077</b>	<b>6,50,298</b>
6.	Less : Other adjustments (Depreciation/Foreign currency loss/other Taxation)	1,11,066	1,83,641
	<b>NET SURPLUS/(DEFICIT)</b>	<b>2,76,011</b>	<b>4,66,657</b>

<b>Statement of Financial Position</b>			
<b>As at 31<sup>st</sup> March 2023</b>			
<b>S.No.</b>	<b>PARTICULARS</b>	<b>Year 2023 (Amt in NZD)</b>	<b>Year 2022 (Amt in NZD)</b>
1.	Current Assets	10,03,910	8,45,751
2.	Non-Current Assets	18,63,231	19,26,347
	<b>TOTAL ASSETS</b>	<b>28,67,141</b>	<b>27,72,098</b>
3.	Current Liabilities	4,65,436	5,06,778
4.	Non-Current Liabilities	5,81,070	7,20,696
	<b>TOTAL LIABILITIES</b>	<b>10,46,506</b>	<b>12,27,474</b>
	<b>NET ASSETS</b>	<b>18,20,635</b>	<b>15,44,624</b>
	<b>TOTAL EQUITY</b>	<b>18,20,635</b>	<b>15,44,624</b>